Антагонисты рецепторов ангиотензина II в лечении больных артериальной гипертонией и сахарным диабетом

Антагонисты рецепторов ангиотензина II в лечении больных артериальной гипертонией и сахарным диабетом

Автор: Журавлева О.А., Кошельская О.А.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Рубрика: Обзоры и лекции

Статья в выпуске: 3-1 т.24, 2009 года.

Бесплатный доступ

В обзоре обобщены современные литературные данные, касающиеся положительных эффектов терапии антагонистами ангиотензина II у пациентов с сочетанием артериальной гипертонии и сахарного диабета. Обобщены и проанализированы результаты клинических и экспериментальных исследований, в которых оценивались антигипертензивные, органопротективные и метаболические эффекты сартанов. Представлен перечень преимущественных показаний к назначению антагонистов рецепторов ангиотензина II (согласно национальным рекомендациям по лечению артериальной гипертонии от 2008 года), обсуждаются возможные перспективные направления использования сартанов.

Еще

Антагонисты рецепторов ангиотензина ii, артериальная гипертония, сахарный диабет

Короткий адрес: https://sciup.org/14919077

IDR: 14919077

Список литературы Антагонисты рецепторов ангиотензина II в лечении больных артериальной гипертонией и сахарным диабетом

  • Drury PL. Hypertension. Ballieres Clin Endocrinol Metab 1988; 2: 375-389.
  • Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framinham Study. J Amer Medic Association 1979; 241: 1225-1229.
  • Cooper M.E., Johnston C.I. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283: 3177-3179
  • Lewis, EJ; Hunsicker, LG; Bain, RP; Rohde, RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11; 329(20):1456-1462.
  • Pahor M., Psaty B.M., Alderman M.H. et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-892.
  • Yusuf S, Sleight P, Pogue J, Bosch J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
  • Dahlцf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003.
  • Yusuf,S et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. The Lancet. Published Online, August 31, 2008; DOI: 10.1016/S01406736(08)61242
  • Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004; 116 (1): 44-49.
  • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ, 1998; 317(7160):713-720.
  • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000;102(1):21-27.
  • The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
  • Комитет экспертов РМОАГ/ВНОК. Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2008; приложение.
  • Pool JL, Guthrie RM, Littlejohn TW et al. Dose-Related Antihypertensive Effects of Irbesartan in Patients With Mild-to-Moderate Hypertension. American Journal of Hypertension 1998; 11, 462-470.
  • Sica DA. Angiotensin-receptor blockade in renal disease: the hard issues. Expert Review of Cardiovascular Therapy 2004; 2(4): 469-471(3).
  • Dzau V: The cardiovascular continuum and rennin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005; 23: S9-S17.
  • Mallion M, Carretta R, Trenkwalder P et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Pressure 2003; 12(suppl 1):36-43.
  • Lacourciиre Y, Krzesinski JM, White WB et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004, 9:203-210.
  • Lindholm LM, Persson M, Alaupovic P et al. Metabolic oucome during 1 year in newly detected hypertensive: results of the Antihypertensive Treat ment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21(8): 1563-1574.
  • Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II.-Annals of Internal Medicine 2008; 48: 1; 16-29.
  • Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardio-vascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.
  • The ONTARGET investigators. Telmisartan, ramipril or both in patientsat high risk for vascular events. NEJM 2008; 358: 1547-1559.
  • Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Eng J Med 2001; 345: 851-860.
  • Brenner BM, Cooper ME, de Zeeuw D et al. Reductions of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL). JRAAS 2000; 1: 328-335.
  • Barnett A. Telmisartan and enalapril in type 2 diabetes. Diabetics Exposed to Telmisartan and Enalapril (DETAIL) study. N Engl J Med 2004; 351; 1952-1961.
  • Viberti G, Wheeldon NM for MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002; 106(6): 672-678.
  • Schrader J, Lunders S, Kulschewski A et al. for MOSES study group. Morbidity and mortality after Stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
  • Schrader J, Luders S, Kulschewski A et al. ACCESS Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in Stroke survivors. Stroke 2003; 34: 1699-1703.
  • Lithell H, Hansson L, Scoog I et al. SCOPE study group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomized double-blind interventional trial. J Hypertension 2003; 21: 875-886.
  • Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan-or amlodipine-based regimens: VALUE, a randomized trial. Lancet 2004; 363: 2022-2031.
  • McMurray JJ. Preventing New-Onset Diabetes and CV Disease in At-Risk Patients: The NAVIGATOR Trial. По URL://http://www.medscape.com/viewarticle/503260_30.
  • Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
  • Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertensio: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.
  • Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21: 1761-1769.
  • Ceriello A, Piconi L, Esposito K, Giugliano D. Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. Diabetes Care 2007; 30: 1694-1698.
  • Schmieder RE, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
  • Karalliedde J, Smith A, De Angelis L et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. J Hypertens 2008; 51: 1617-1623.
  • Uchida H, Nakamura Y, Kaihara M et al. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
  • Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
  • Stumpe K O, Agabiti-Rosei E, Zielinski T et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Therapeutic Advances in Cardiovascular Disease (2007); 1(1): 1-6.
  • Schrader J, Hammersen F, Lüders S. et al. für die MOSES-Studiengruppe. Morbidität und Mortalität nach Schlaganfall bei Patienten mit Diabetes mellitus (MOSES). Journal für Hypertonie 2006; 10 (2): 9-12-X.
  • Fournier A, Messerli FH, Achard JM et al. Cerebroprotection Mediated by Angiotensin II. A Hypothesis Supported by Recent Randomized Clinical Trials. Journal of the American College of Cardiology 2004; 43:8:1343-1347.
  • Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336.
  • Fogari R, Mugellini A, Destro M et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Phatmacol 2006; 47: 46-50.
  • McEwan PE, Gray GA, Sherry L et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98: 2765-2773.
  • Goette A, Arndt M, Rocken C et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
  • Webster MW, Fitzpatrick MA, Nicholls MG et al. Effect of enalapril on ventricular arrhthmias in congestive heart failure. Am J Cardiol 1985; 56: 566-569.
  • Healey J, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysis. J Am Coll Card 2005; 45: 1832-1838.
  • Nickening G, Jung O, Strehlow K et al. Hypercholesterolemia is associated with enhanced angiotensin AT1 receptor expression. Am J Physiol 1997; 272: 2701-2707.
  • Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol 2006; 38: 766-781.
  • Pershadsingh HA, Kurtz TW. Insulin-sentizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015.
  • Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27(7): 457-464.
  • Vitale C, Mercuro G, Castiglioni C et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
  • Honjo S, Nichi Y, Wada Y et al. Possible Beneficial Effect of Telmisartan on Glycemic Control in Diabetic Subjects. Diabetes Care 2005; 28: 498.
  • Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625-1631.
  • Kranzhöfer, R; Schmidt J, Pfeiffer CA et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscier Thromb Vasc Biol 1999; 19: 1623-1629.
  • Fliser D, Buchholz K et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110(9): 11031107.
  • Dang A, Zhang Y et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. Journal of Human Hypertension 2006; 20; 45-50.
  • Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a new work meta-analysis. Lancet 2007; 369: 201-207.
  • Brillante DG, O'sullivan AJ, Johnstone MT, Howes LG. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes, Obesity & Metabolism 2008; 10(2): 143-150.
  • Ogawa S, Mori T, Nako K et al. Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy. Hypertension 2006; 47: 699-705.
  • Barkis G, Burgess E, Weir M et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International 2008; 74: 364-369.
  • Turnbull F, Neal B, Pfeffer M et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25: 951-958.
  • The weight of evidence mounts for ARBs. По URL: http://www.theheart.org/article/875479.do.
  • Mogensen CE, Neldam S, Tikkanen I et al. Ran domised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbumin uria (CALM) study. Br Med J 2000; 321: 1440-1444.
  • Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis. Lancet 2005; 366: 2026-2033.
  • Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin-angiotensin system on proteinuria in renal disease. Ann Int Med 2008; 148: 30-48.
  • Saunders E, Cable G, Neutel J. Predictors of Blood Pressure Response to Angiotensin Receptor Blocker/Diuretic Combination Therapy: A Secondary Analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) Study. The Journal of Clinical Hypertension; 10(1): 27-33.
  • Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardio-vascular events with with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
  • Jamerson KA, on behalf of the ACCOMPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. American College of Cardiology Scientific Sessions; March 31, 2008; Chicago, IL.
  • Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563-580.
  • Smith TR, Philipp T, Vaisse B et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007; 9: 355-364.
  • Poldermans D, Glazes R, Kargiannis S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279-289
  • Allemann Y, Fraile B, Lambert M et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens 2008; 10.
  • Trenkwalder P, R Schaetzl R, Borbas E et al. Efficacy and safety of the combination of amlodipine10/valsartan160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5-The ExPress-C. Trial Dtsch med Wochenschr. 2006; 131 DOI: 10.1055/s-2006-956640
  • Kawamori R, Daida H, Tanaka Y, Miyauchi K et al. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). BMC Cardiovasc Disord 2006; 6: 39.
  • Halimi S. Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study. Presse Med 2005; 34(18):1300-1302.
  • Massie BM, Carson PE, McMurray JJ et al. for the I-PRESERVE Investigators. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. По URL: www.nejm.org November 11, 2008 (10.1056/NEJMoa0805450).
  • По URL: htpp://clinicaltrials.gov.
Еще
Статья научная
SciUp 2024 © 2024 ©